Financials and Corporate

Innate Pharma SA announces its financial results for 2007: Moderate burn rate in the context of continuing clinical effort and pipeline maturation.

Innate Pharma SA announces the recruitment of Mr. Hemanshu Shah as CBO, in the context of the start of its operations in the USA.

Innate Pharma SA announces a turnover of 1.5 million euros for the first quarter of 2008, compared with 1.5 million euros for the same period in 2007.

Innate Pharma S.A. will hold its Annual General Meeting of Shareholders on June 27, 2008, in Marseilles, France. An information meeting open to shareholders, analysts, investors and journalists will...

Innate Pharma SA has released the total number of shares outstanding and voting rights, as of April 30, 2008.

Innate Pharma SA announces the outcome of its AGM that took place on June 27, 2008, in Marseilles and updates on the divestment process by Novo Nordisk A/S of its rights to IPH 2101.

Innate Pharma SA announces 4.4 million Euros in turnover for the first semester of 2008. Cash, cash equivalents and current financial instruments at the end of June 2008 amounted to 43.0 million euros...

Innate Pharma SA announces its financial results for the first half of 2008. Results for the first half of 2008 show a stable operational loss (4.7 million euros for the six-month period ended June 30...

Innate Pharma SA announces that it has acquired the worldwide exclusive development and commercial rights to IPH2101 from Novo Nordisk A/S in the context of a swap of products.

Innate Pharma SA announces a turnover of 5.9 million euros for the first nine months of 2008, compared with 5.1 million euros for the same period in 2007.